本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 虹软科技股份有限公司（以下简称公司）第三届监事会第五次会议通知于 2025 年 8 月 5 日以电子邮件等书面方式送达全体监事，会议于 2025 年 8 月 15 日在公司会议室以现场会议的方式召开。本次会议应出席监事 3 人，实际出席监 事 3 人。本次会议由监事会主席刘晓倩女士主持，公司董事会秘书列席会议。本 次会议的召集、召开和表决情况符合法律、行政法规、部门规章、规范性文件以 及《公司章程》《监事会议事规则》的相关规定。 证券代码：688088 证券简称：虹软科技 公告编号：临 2025-033 虹软科技股份有限公司 第三届监事会第五次会议决议公告 第 1 页 / 共 2 页 二、监事会会议审议情况 本次会议以记名投票方式审议通过了以下议案： （一）审议通过了《2025 年半年度报告及其摘要》 经审核，监事会认为： 1、公司《2025 年半年度报告及其摘要》的编制和审议程序符合法律、法规、 公司章程和公司内部管理制度的各项规定； 2、半年度报告 ...

，我将尽力为您提供帮助。请您提供更多信息，以便我能更好地理解您的需求。 例如，您可以告诉我： * **您想让我做什么？** 是要我写一篇文章、回答一个问题、提供建议、翻译文本，还是其他什么？ * **您想让我处理什么内容？** 是关于某个主题、某个文件、某个概念，还是其他什么？ * **您有什么具体要求或限制吗？** 例如，字数限制、语言要求、风格偏好、需要包含哪些信息，或者不能包含哪些信息？ 您提供的信息越详细，我越能准确地理解您的意图，并为您提供高质量的帮助。

2025 年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688088 证券简称：虹软科技 公告编号：临 2025-032 虹软科技股份有限公司 虹软科技股份有限公司（以下简称公司）2025 年半年度合并报表中归属于 上市公司股东的净利润为人民币 88,536,072.16 元。截至 2025 年 6 月 30 日，公 司母公司报表中期末未分配利润为人民币 217,836,010.65 元。上述财务数据未 经审计。经董事会决议，公司 2025 年半年度拟以实施权益分派股权登记日登记 的总股本扣减公司回购专用证券账户中的股份为基数分配利润。本次利润分配方 案如下： 公司拟向全体股东每 10 股派发现金红利 2.20 元（含税），不进行资本公积 金转增股本，不送红股。截至 2025 年 8 月 15 日，公司总股本 401,170,400 股， 扣减回购专用证券账户中的股份数 439,000 股，以此计算合计拟派发现金红利 88,160,908.00 元（含税），占公司 2025 年半年度归 ...

Core Insights - The animal health sector experienced a significant increase of 3.86% on August 15, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] Stock Performance - Shenlian Biological (688088) saw a closing price of 10.69, with a remarkable increase of 19.98% and a trading volume of 435,300 shares, amounting to a transaction value of 441 million yuan [1] - Other notable performers included: - Biological Shares (600201) with a closing price of 8.93, up 6.06% [1] - Ruipu Biological (300119) with a closing price of 22.78, up 5.56% [1] - KQ Biological (688526) with a closing price of 17.24, up 2.44% [1] Capital Flow - The animal health sector saw a net inflow of 49.48 million yuan from institutional investors, while retail investors contributed a net inflow of 40.08 million yuan [1] - Notably, retail funds experienced a net outflow of 89.56 million yuan [1] Detailed Capital Flow Analysis - Shenlian Biological had a net inflow of 54.78 million yuan from institutional investors, while it faced a net outflow of 41.10 million yuan from speculative funds [2] - Biological Shares had a net inflow of 14.26 million yuan from institutional investors, with a net outflow of 33.08 million yuan from speculative funds [2] - Ruipu Biological recorded a net inflow of 1.78 million yuan from institutional investors, while speculative funds saw a net outflow of 16.93 million yuan [2]

从资金流向上来看，当日动物保健板块主力资金净流出1.41亿元，游资资金净流入2186.09万元，散户资 金净流入1.19亿元。动物保健板块个股资金流向见下表： 证券之星消息，8月14日动物保健板块较上一交易日下跌2.12%，申联生物领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688088 | 申联生物 | 8.91 | -5.91% | 19.42万 | 1.78亿 | | 838275 | 驱动力 | 9.28 | -4.82% | 3.69万 | 3494.87万 | | 839729 | 永顺生物 | 9.44 | -4.55% | 4.10万 | 3941.86万 | | 871970 | 大禹生物 | 9.46 | -3.86% | - 3.57万 | 3418.13万 | | 300871 | 回盛生物 | 21.96 | -2.87% | 12 ...

Market Overview - The animal health sector experienced a decline of 0.93% on August 12, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3665.92, up 0.5%, while the Shenzhen Component Index closed at 11351.63, up 0.53% [1] Individual Stock Performance - *ST Lvkang (002868) closed at 28.96, up 4.81% with a trading volume of 17,300 and a turnover of 49.30 million [1] - Ruipu Biological (300119) closed at 21.98, up 0.69% with a trading volume of 73,700 and a turnover of 162 million [1] - Shunlian Biological (688088) closed at 9.47, down 4.92% with a trading volume of 260,700 and a turnover of 255 million [2] - Other notable declines include Haili Biological (603718) down 3.94% and Huifeng Biological (300871) down 2.70% [2] Capital Flow Analysis - The animal health sector saw a net outflow of 270 million from institutional investors, while retail investors contributed a net inflow of 174 million [2] - The detailed capital flow indicates that *ST Lvkang had a net inflow of 7.34 million from institutional investors, while Shunlian Biological experienced a net outflow of 20.93 million [3] - Retail investors showed significant interest in Huifeng Biological, with a net inflow of 62.24 million [3]

Core Viewpoint - The upcoming unlocking of shares for the first batch of companies listed on the Sci-Tech Innovation Board (STAR Market) is expected to have limited impact on the secondary market, as many major shareholders are voluntarily extending their lock-up periods or committing not to sell their shares immediately after the unlocking, reflecting confidence in the long-term value of their companies [1][2][4]. Group 1: Shareholder Actions - Nine companies have announced that their major shareholders will extend the lock-up period by 6 to 12 months or commit not to sell shares for six months post-unlocking, representing a market value of 808 billion yuan, which is over 40% of the total theoretical unlocking market value for the first batch of 25 companies [2][4]. - Major shareholders of companies like China Communication Signal and Rongbai Technology have voluntarily chosen not to unlock their shares, indicating strong confidence in their companies' future [2][3]. Group 2: Market Impact and Stability - The unlocking of shares does not equate to immediate selling, as different shareholders have varying intentions regarding exiting their positions, and any selling will be subject to strict regulations [4][5]. - The potential selling pressure from unlocking is mitigated by the fact that major shareholders and executives are limited in how much they can sell within a specified timeframe, which helps maintain market stability [3][4]. Group 3: Long-term Investment Value - The overall performance of companies on the STAR Market has shown strong growth, with a compound annual growth rate of 28% in revenue and 70% in net profit from 2019 to 2021, indicating robust long-term investment potential [6]. - The STAR Market is expected to attract long-term capital as liquidity improves post-unlocking, creating favorable conditions for institutional investors [6][7]. Group 4: Regulatory Environment - The STAR Market has implemented a unique inquiry transfer system for share reductions, which has proven effective in maintaining market stability and minimizing price fluctuations during share sales [5][6]. - Recent regulatory developments, such as the introduction of market-making trading rules, are anticipated to enhance liquidity and reduce market volatility, further supporting the STAR Market's growth and stability [7].

Group 1 - The core viewpoint of the news is that Hongsoft Technology (688088) has shown positive financial performance in the first quarter of 2025, with significant growth in revenue and net profit [1] - As of August 11, 2025, Hongsoft Technology's stock closed at 48.95 yuan, up 1.58%, with a trading volume of 55,300 lots and a transaction amount of 270 million yuan [1] - The company's latest quarterly report indicates total operating revenue of 209 million yuan, a year-on-year increase of 13.77%, and a net profit attributable to shareholders of 49.66 million yuan, up 45.36% year-on-year [1] Group 2 - Hongsoft Technology has made investments in 21 companies and participated in 21 bidding projects, indicating active engagement in business expansion [2] - The company holds 76 trademark registrations and 173 patents, showcasing its commitment to intellectual property and innovation [2] - Hongsoft Technology was established in 2003 and is primarily engaged in software and information technology services, with a registered capital of 401.17 million yuan [1][2]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The release of the GPT-5 model by OpenAI marks a significant enhancement in performance compared to its predecessor, with notable improvements in programming capabilities and various fields such as mathematics and health [5][6] - The reduction in hallucination rates and significant price drops for the GPT-5 model are expected to promote the commercialization of AI applications [7] - The report maintains a strong outlook for the rise of the AI Agent industry in 2025, highlighting potential beneficiaries in the AI programming and multimodal sectors [8] Summary by Sections Industry Trends - The industry is experiencing a positive trend with a projected increase in AI applications, particularly following the advancements brought by GPT-5 [1][5] Model Performance - GPT-5 shows a remarkable performance increase, especially in programming, achieving a score of 74.9% in SWE-bench Verified tests, surpassing previous models [6] - In various tests, GPT-5 has set new benchmarks in mathematics, multimodal understanding, and health, indicating its advanced capabilities [6] Market Impact - The significant reduction in the cost of using GPT-5, with input and output prices at $1.25 and $10 per million tokens respectively, is expected to enhance market penetration and application deployment [7] - The report identifies several companies as potential beneficiaries of the AI application boom, including Wanxing Technology, Meitu, and Kuaishou, among others [8]

计算机ETF（159998）跟踪中证计算机主题指数（930651.CSI）。该指数以中证全指为样本空间，选取 涉及信息技术服务、应用软件、系统软件、电脑硬件等业务的上市公司股票作为成分股。截至8月6日， 该ETF前十大重仓股包括科大讯飞、海康威视、中科曙光、金山办公、同花顺、浪潮信息、恒生电子、 紫光股份、润和软件、三六零等龙头。计算机ETF（159998）配有场外联接基金（A类：001629/C类： 001630）。 8月7日，三大指数集体走低，截至发稿上证综指下跌0.05%，深证成指下跌0.68%，创业板指跌1%。中 证计算机主题指数(930651.CSI)跌0.73%，该指数成分股中，用友网络上涨超5%，卫宁健康上涨近3%， 三六零与虹软科技等4只个股上涨超1%。 相关ETF方面，计算机ETF（159998）截至发稿下跌0.85%。资金流向方面，该ETF上个交易日(8月6日) 净流入额为2032.42万元，截至上个交易日，已连续4个交易日"吸金"（获资金净流入），累计净流入额 为9422.46万元。截至8月6日，该ETF最新流通份额为38.65亿份，最新流通规模为36.5亿元，居全市场 计算机类ETF产 ...